Amundi 13F: Adds $2.8B to AstraZeneca (AZN) Stake

Amundi Expands AstraZeneca PLC Position

Amundi filed a Form 13F with the Securities and Exchange Commission revealing a large change in its investment portfolio for AstraZeneca PLC (NYSE: AZN). The institutional investor boosted its holdings by adding 15,375,659 shares during the period. That move grew its stake by 146,574.4% compared to the prior quarter.

Position Details and Valuation

The massive addition brought Amundi's total ownership to 15,386,149 shares of the drug manufacturer. Based on reporting metrics, the firm's expanded stake carries a reported value of about $2.8 billion. This backward-looking filing reflects holdings as of the reporting period and may not represent the investor's current position today.

Stock Valuation and Trading Levels

AstraZeneca shares have traded through a 52-week range of $145.80 to $212.71. The stock changes hands around the $182.28 mark, sitting near its 200-day moving average of $182.92. The company operates with a trailing P/E ratio of 25.16 and a forward P/E ratio of 14.52.

Recent Earnings Performance

AstraZeneca reported annual revenue of $61.37 billion alongside a net margin of 17.0%. The biopharmaceutical firm generated earnings of $6.68 per share with a return on equity of 22.0%. Investors can look ahead to the company's next earnings report scheduled for October 30, 2026, for further updates on revenue and clinical pipelines.

Dividend Metrics

The company distributes an annual dividend rate of $3.20 per share, giving the stock a dividend yield of 1.93%. This payout is supported by a dividend payout ratio of 47.41%, leaving room for retained earnings while returning capital to shareholders.

Analysts Set New Price Targets

On August 24, 2026, CICC initiated coverage on AstraZeneca with an Outperform rating and a $198.00 price target. Across the wider analyst community, the stock holds a consensus rating of Strong Buy backed by 11 analyst opinions and a mean price target of $212.17.

Company Background and Business Operations

AstraZeneca is a Cambridge, United Kingdom-based biopharmaceutical enterprise focused on discovering, developing, and commercializing prescription medications for oncology, rare diseases, and specialty care. Led by CEO Pascal Soriot, the firm employs 96,100 workers globally and maintains research partnerships focused on advanced artificial intelligence models and oncology treatments.

Outlook and Regulatory Filings

Institutional investors and market participants continue to monitor large quarterly disclosures for shifting portfolio strategies among major asset managers. Because 13F filings are historical documents submitted weeks after a quarter ends, they offer a retrospective view of institutional positioning rather than real-time trading data.